• The minimal clinically important difference of QoL measure scores is underreported.
• There is inconsistent reporting of QoL data and a need for guidelines when reporting.
From the perspective of the patient with psoriasis, quality-oflife (QoL) improvement is as important as improvement in clinical signs. 1 Health-related QoL instruments are increasingly used as outcome measures [2] [3] [4] [5] in assessing interventions. 6, 7 Types of health-related QoL instruments used include generic, specialty-specific and disease-specific measures; specific tools are perceived as more relevant and thus preferred by patients. 8 Previous reviews have examined the impact of psoriasis interventions on QoL.
9-12 De Korte et al. 9 reviewed QoL data with clinical and demographic correlations. Kitchen et al. 13 carried out a systematic review of patient-reported outcome measures and evidence of their validation in psoriasis. These reviews underscored the value of QoL measurement in psoriasis. However, we need to understand how QoL has been reported in previous trials; a comprehensive review is needed of the use of QoL instruments in randomized controlled trials (RCTs) for interventions in psoriasis. The aims of this systematic review were to identify RCTs of therapies in psoriasis that have assessed QoL, and to evaluate patterns of utility and reporting of QoL data. This systematic review should reveal how QoL instruments have been used across therapeutic trials, including consideration of the minimal clinically important difference (MCID), frequency of measurement and sensitivity to change. The review may be useful for those who wish to understand the patterns of use of QoL measures in interventional trials for psoriasis.
Materials and methods

Data sources
We searched six computerized bibliographical databases up to November 2014: Cochrane Library CENTRAL, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, Embase, Web of Science Core Collection and Scopus. The search was restricted to publications in English and was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Prospero registration no. CRD42015009193).
Keywords were formulated using Scottish Intercollegiate Guidelines Network and Cochrane search filters for RCTs, and ScHARR search filters for QoL. Keywords for psoriasis treatments were developed through a pilot search of other systematic reviews on psoriasis treatments and of the British National Formulary. The search filters used are given in Appendix S1 (see Supporting Information). We ran supplementary searches and reviewed trial registers and grey literature. Reference lists of all included studies and of recent reviews were also assessed. Electronic publications in advance of print were also included.
Selection criteria
We included RCTs of any psoriasis treatment using at least one QoL instrument in adults (aged ≥ 18 years) with psoriasis, of either sex and of any ethnicity, including all subtypes of psoriasis. Psoriatic arthritis trials were included only if a skin-specific QoL instrument was used to differentiate QoL impairment for arthritis from that of psoriasis.
Exclusion criteria
The exclusion criteria for the systematic review were as follows: psoriatic arthritis studies where it was not possible to differentiate data on QoL impact of arthritis from QoL impact of psoriasis, studies that included any patient aged < 18 years, and articles where the change in QoL values could not be reliably calculated (including graphical representation). For consistency, QoL data presented only as subscales, where total scores are usually calculated, were excluded. Abstracts and posters where further data were not available upon contacting the author were also excluded.
Outcome measures extracted
Primary outcomes recorded included the QoL instrument used; scores at baseline, treatment and follow-up end points; and change in QoL attributed to treatment. For studies with an open-label extension, the data were extracted only for the period of the study while it was randomized and controlled. For crossover trials, the data were extracted prior to the crossover.
Secondary outcomes were Psoriasis Area and Severity Index (PASI) score or any other psoriasis severity scale used.
Data extraction and synthesis
Two reviewers (F.M.A. and A.C.C.) extracted data independently from all eligible published studies, discussed any disagreements and, if necessary involved a third reviewer (A.A.A.) for resolution. We adapted a form, which included the Cochrane Risk of Bias tool, for recording data 14 that included study design, details of administration, methodological quality and duration of treatment and follow-up. Article quality was quantitatively rated using the Jadad score. 15 We recorded PASI or any other psoriasis severity scale and all QoL data including the baseline, treatment and follow-up end-point scores and whether the studies detailed QoL percentage change, full scores, graphs or MCID.
Results
Of 3646 screened records, 99 articles met the inclusion criteria, describing 100 RCTs and 33 215 patients (Fig. 1) . Some trials were reported in more than one publication; all relevant references are given in Table 1 . Sixty-three studies were placebo controlled, 33 were head to head and 36 tested a single drug in different dosage regimens or formulations (some studies fulfilled more than one criterion). Although Jadad scores 15 were not integral to the inclusion criteria, Table 1 ranks interventions from low to high methodological quality for each intervention. Of the 100 trials that measured QoL, 33 tested topical, 18 systemic, 39 biologics, nine phototherapy and 10 other interventions, including educational treatments, diet, writing exercises, balneotherapy, auriculotherapy, relaxation therapies and interdisciplinary care (Table 1 ; Fig. 2 ). The numbers of studies reporting each topical intervention were calcipotriol (13 trials), calcipotriol/betamethasone (seven), clobetasol (four) and dithranol (four). Systemic medications included methotrexate (seven), ciclosporin (three) and voclosporin (two). Biological trials included etanercept (14) , ustekinumab (eight), adalimumab (seven), infliximab (six) and alefacept (four). QoL was evaluated in nine phototherapy trials. In the category of 'other interventions', QoL was used most commonly in educational (three) and diet (three) studies.
The mean Jadad score was 3Á34 (range 1-5; Table 1 ). QoL was tested a range of two to six times for topical, two to 25 times for systemic and two to 12 times for biological interventions. Sixteen trials lasted > 12 weeks, 49 lasted 12-24 weeks and 35 lasted > 24 weeks. The number of patients ranged from 20 16 to 2546, 17 with a mean male-to-female ratio of 1Á7 : 1 per study arm. The mean PASI at baseline ranged from 1Á7 to 33Á1. The ranges of mean QoL scores at baseline were Dermatology Life Quality Index (DLQI) 1Á7-20Á1 (range for this measure = 0-30); 36-Item Short Form Survey (SF-36) physical component summary (PCS) 32Á7-56Á2 (0-100) and mental component summary (MCS) 35Á7-52Á4 (0-100); EuroQoL-5D (EQ-5D) component I 0Á48-0Á74 (0-1) and component II 55Á3-76Á4 (0-100); and Psoriasis Disability Index (PDI) 7Á6-52Á6 (0-90).
Instruments used
Thirteen instruments were used to measure QoL; some studies used more than one. Five generic instruments used were the SF-36, 18 EQ-5D, 19 General Health Questionnaire, 20, 21 Quality of Life Index 22 and Sickness Impact Profile. 23, 24 In addition, four dermatology-specific instruments were used, three specific to psoriasis and one for scalp dermatitis: DLQI, 25 Skindex, 26 Dermatology Quality of Life Scales, 27 Freiburg Life Quality Assessment, 28 PDI, 24 12-Item Psoriasis Quality of Life Questionnaire, 29 Psoriatic Arthritis Quality of Life measure 30 and Scalpdex. 31 Of these, the DLQI was the most commonly used QoL instrument (83 studies, 83%), followed by the SF-36 (31, 31%), EQ-5D (15, 15%), PDI (14, 14%) and Skindex (five, 5%).
Minimal clinically important difference and statistical reporting
Of the 100 trials identified, 37 reported MCID; 32 were for DLQI, 10 for SF-36 and six for EQ-5D. The DLQI MCID was considered to be a score change of five, 32 but is now reported as four. 33 Figure 3 shows the correlations between PASI and absolute DLQI (R 2 = 0Á49) and percentage (R 2 = 0Á64) score changes, where available. In some cases the correlation was weak, 43 possibly attributed to nonoptimal end-point measurement for QoL, where the maximum effect may be missed. 44 Furthermore, some interventions may have a psychological impact not captured by clinical parameters. Table 1 gives the studies included that documented full QoL data and statistical significance for intervention vs. comparator. Significant changes were reached in 52 trials for the DLQI, 19 for the SF-36, five for both EQ-5D and the PDI and two for Skindex. Conversely there was no statistical improvement in 19 trials for the DLQI, six for the SF-36, three for EQ-5D, six for the PDI and three for Skindex. Twelve trials did not report statistical significance for the DLQI, six for the SF-36, four for EQ-5D and two for the PDI.
The first two studies identified that fulfilled the inclusion criteria were published in 1998. 45, 46 Since then, reports of 
Discussion
QoL assessment is a frequent component in assessing psoriasis treatment efficacy. 47 This systematic review has identified therapeutic RCTs that demonstrated extractable QoL data, inevitably with heterogeneity in design, disease severity and QoL reporting. Many trials were excluded because of inconsistent reporting and analysis of QoL (Fig. 1) . 48 Baseline and end-of-treatment values were not always provided. Often QoL scores were presented as percentage or value changes without pre-or postintervention scores. Mean values were most commonly reported, although median values are preferable with ordinal data. 47 Standard deviations, P-values or confidence intervals were sometimes omitted, and intention-to-treat numbers were sometimes omitted from the QoL dataset. This presented challenges for synthesizing data. The MCID is the minimal change in score that is considered of clinical relevance. 49 Of the 13 QoL instruments used, only the DLQI, SF-36 and EQ-5D have MCID values reported in the was the only other used instrument with known MCID; these data are not reported as the numbers were so low. The MCID of QoL measures may be determined using several methodologies, and at least nine approaches have been reported. 50 These may be categorized into two main groups:
anchor-based and distribution-based approaches. Whereas the former incorporates the patient perspective, the latter determines MCID using statistical significance. The anchor-based method is the most commonly used for determining the MCID, as used in the case of the DLQI. 33 Each methodology has its limitations. For example, anchorbased methods have often been criticized for unequal changes required for deterioration vs. improvement of a condition. 51 Several factors may influence MCID scores, including patient baseline status, disease group and severity, treatment, and patient demographics. Furthermore, it is important to note that MCID values may differ significantly within the same population depending on the methodology chosen. 52 Therefore, interpreting MCID scores should be considered in the context of these limitations. More generic QoL instruments were used (n = 5) than specialty-(n = 4) or condition-specific questionnaires (n = 3). The DLQI was the most commonly used instrument, possibly because of the simplicity of reporting a single summary score, the ease of completion in 2 min, 53 its widespread use in national psoriasis guidelines, 54 and other reasons. 55 The frequency of QoL measurement varied across studies depending on intervention type and trial duration. The U.K. guidelines, which recommend DLQI measurement at 10-16 weeks depending on the biologic, may not capture the best DLQI responses for biological therapies. 44 Several reviews have explored the effects of biological treatment on QoL. 10, 11, 56, 57 Other systematic reviews have explored QoL in psoriasis; the review by De Korte et al. 9 was not limited to RCTs and this provided difficulties in interpreting the dataset. The current systematic review investigates the patterns of use of QoL instruments, as well as the reporting of the outcomes. We employed strict entry criteria, allowing for robust comparison across interventions per QoL instrument. We included only data from the double-blind controlled phases of each trial. Nevertheless, the lack of adequate guidelines on QoL data reporting still rendered data analysis problematic.
Kitchen et al. 13 reviewed the ability of psoriasis-specific instruments to capture adequately domains relating to psoriasis: no existing psoriasis-specific patient-reported outcome instrument has sufficient evidence on validity, reliability and sensitivity to change, but both DLQI 58 and Skindex demonstrated content validity. However, this systematic review demonstrates that several generic and disease/specialty-specific instruments were sensitive to change with positive QoL outcomes. The DLQI and SF-36 are the most frequently used instruments across psoriasis RCTs. A European S3 guidelines report on psoriasis systemic treatment 59 described the DLQI as an 'important' variable in assessment of treatment efficacy. However, the DLQI has limitations, including previous criticisms of its unidimensionality and low representation of emotional aspects. 60 There is diverse practice in monitoring therapeutic effect on QoL and questionnaire preference. We rejected 113 RCTs because of inextricable QoL data. The European Academy of Dermatology and Venereology Task Force provides recommendations for use of QoL measures. 61 Currently there is great variation in the quality of reporting of QoL data, 62, 63 creating difficulties in cross-interventional meta-analyses. This systematic review emphasizes the need for guidelines concerning appropriate reporting of QoL data. This review has several limitations. Only English-language literature was examined and only studies with extractable QoL data were included. There was too little comparative information from other QoL instruments to be included. Several studies were excluded due to inadequate QoL data reporting. Collating data across studies other than RCTs was not possible due to the wide variation in methodologies. Although an author (A.Y.F.) is joint DLQI copyright holder, bias was countered by two independent principal reviewers conducting the data search, extraction and synthesis, with a third independent adjudicator reviewer. We recommend improvement of QoL reporting to include baseline, treatment and follow-up end-point absolute median scores with interquartile ranges. Patient numbers should always be reported, as well as whether intention to treat was implemented, as previously suggested. 62, 63 If a graphical representation of QoL is published, it should be accompanied by numerical data. Authors should not submit only percentage and/or graphical data to represent study outcomes, as these data cannot be used in meta-analysis and systematic reviews. Journals should furthermore implement such criteria prior to accepting publications. The MCID and validated band descriptors where available should be used to interpret data, as this holds greater clinical value than statistical significance alone. Researchers should consider the availability of MCID when choosing QoL instruments, and be encouraged to publish MCID information. While there are numerous approaches for calculating MCID scores, there is a need for consensus on new or improved methodological approaches towards calculating MCID. Existing methodologies should be cautiously taken into account by clinicians and researchers alike to facilitate the interpretation of results. Although minimal change is clinically important, the question arises of whether intervention end points should target perfect QoL, rather than demonstrating a measurable improvement.
